Form 8-K - Current report:
SEC Accession No. 0001683168-23-003210
Filing Date
2023-05-11
Accepted
2023-05-11 16:59:44
Documents
15
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sunshine_8k.htm   iXBRL 8-K 27332
2 PRESS RELEASE sunshine_ex9901.htm EX-99.1 11332
7 GRAPHIC image_001.jpg GRAPHIC 6358
  Complete submission text file 0001683168-23-003210.txt   269081

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE sbfm-20230511.xsd EX-101.SCH 3490
4 XBRL DEFINITION FILE sbfm-20230511_def.xml EX-101.DEF 26585
5 XBRL LABEL FILE sbfm-20230511_lab.xml EX-101.LAB 36550
6 XBRL PRESENTATION FILE sbfm-20230511_pre.xml EX-101.PRE 25209
9 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 5390
Mailing Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5
Business Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5 514-426-6161
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

EIN.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41282 | Film No.: 23911971
SIC: 2834 Pharmaceutical Preparations